Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
The Tampa Bay Lightning are in the mix for one of the top three spots in the Atlantic Division. It's a neck-and-neck race and the team is currently occupying a wild-card spot. If the Lightning are ...
In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line treatment, with a 77% objective response rate and 96% disease control rate.
NCCN upgrades Trodelvy to category 1 preferred first-line therapy for metastatic TNBC with CPS <10 and no germline BRCA1/2 mutation. For PD-L1–positive metastatic TNBC (CPS ≥10), Trodelvy plus ...
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Please provide your email address to receive an email when new articles are posted on . Immune checkpoint inhibitor-based combinations are the preferred first-line therapy for metastatic clear cell ...
Findings showed datopotamab deruxtecan significantly improved PFS and OS vs chemotherapy. Topline data were announced from a phase 3 trial evaluating datopotamab deruxtecan-dlnk as a first-line ...
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results